Fox News: GPC Biotech Announces Initiation of NCI-Sponsored Phase 2 Trial of Satraplatin in Patients with Metastatic Hormone-Refractory Prostate Cancer Previously Treated with Docetaxel

[riky]

GPC Biotech Announces Initiation of NCI-Sponsored Phase 2 Trial of Satraplatin in Patients with Metastatic Hormone-Refractory Prostate Cancer Previously Treated with Docetaxel
     

Study seeks to determine if presence of certain gene impacts
                            patient outcome<img src="You are not allowed to view links. Register or Login" height="1" width="1"/><img src="You are not allowed to view links. Register or Login" height="1" width="1"/>
     

You are not allowed to view links. Register or Login